Article
CCL3L1-CCR5 genotype influences durability of immune recovery during antiretroviral therapy of HIV-1-infected individuals.
Nature medicine - 1 Apr 2008
Ahuja Sunil K, Kulkarni Hemant, Catano Gabriel, Agan Brian K, Camargo Jose F, He Weijing, O'Connell Robert J, Marconi Vincent C, Delmar Judith, Eron Joseph, Clark Robert A, Frost Simon, Martin Jeffrey, Ahuja Seema S, Deeks Steven G, Little Susan, Richman Douglas, Hecht Frederick M, Dolan Matthew J
Abstract excerpt
The basis for the extensive variability seen in the reconstitution of CD4(+) T cell counts in HIV-infected individuals receiving highly active antiretroviral therapy (HAART) is not fully known. Here, we show that variations in CCL3L1 gene dose and CCR5 genotype, but not major histocompatibility complex HLA alleles, influence immune reconstitution, especially when HAART is initiated at <350 CD4(+) T cells/mm(3)....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.